CD19 and acute lymphoblastic leukemia: Tisagenlecleucel, an autologous anti-CD19/4-1BB/CD3z CAR-T, was studied in the phase I/IIa ELIANA trial in which pediatric and young adult patients with CD19+ relapsed or refractory B-ALL were treated.